Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences

1 E. A. Salsitz, Chronic pain, chronic opioid addiction: a complex nexus, J. Med. Toxicol. 12(1) (2016) 54–57; https://doi.org/10.1007/s13181-015-0521-9 Search in Google Scholar

2 A. Schuchat, G. P. Guy, Jr. and D. Dowell, Prescription drug monitoring programs and opioid death rates-reply, JAMA 318(20) (2017) Article ID 2045; https://doi.org/10.1001/jama.2017.16304 Search in Google Scholar

3 R. Lumish, J. K. Goga and N. J. Brandt, Optimizing pain management through opioid deprescribing, J. Geront. Nurs. 44(1) (2018) 9–14; https://doi.org/10.3928/00989134-20171213-04 Search in Google Scholar

4 A. Owusu Obeng, I. Hamadeh and M. Smith, Review of opioid pharmacogenetics and considerations for pain management, Pharmacotherapy 37(9) (2017) 1105–1121; https://doi.org/10.1002/phar.1986 Search in Google Scholar

5 B. S. Haerian and M. S. Haerian, OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis, Pharmacogenomics 14(7) (2013) 813–824; https://doi.org/10.2217/pgs.13.57 Search in Google Scholar

6 J. Muriel, C. Margarit, J. Barrachina, P. Ballester, A. Flor, D. Morales, J. F. Horga, E. Fernández and A. M. Peiró, Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients, Basic Clin. Pharmacol Toxicol. 124(4) (2019) 439–448; https://doi.org/10.1111/bcpt.13155 Search in Google Scholar

7 G. Ruano and J. A. Kost, Fundamental considerations for genetically-guided pain management with opioids based on CYP2D6 and OPRM1 polymorphisms, Pain Phys. 21(6) (2018) E611–E621. Search in Google Scholar

8 V. Haufroid and P. Hantson, CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants, Clin Toxicol. (Philadelphia) 53(6) (2015) 501–510; https://doi.org/10.3109/15563650.2015.1049355 Search in Google Scholar

9 K. R. Crews, A. A. Monte, R. Huddart, K. E. Caudle, E. D. Kharasch, A. Gaedigk, H. M. Dunnenberger, J. S. Leeder, J. T. Callaghan, C. F. Samer, T. E. Klein, C. E. Haidar, S. L. Van Driest, G. Ruano, K. Sangkuhl, L. H. Cavallari, D. J. Müller, C. A. Prows, M. Nagy, A. A. Somogyi and T. C. Skaar, Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy, Clin. Pharmacol. Ther. 110(4) (2021) 888–896; https://doi.org/10.1002/cpt.2149 Search in Google Scholar

10 M. Matic, S. N. de Wildt, D. Tibboel and R. H. N. van Schaik, Analgesia and opioids: A pharmacogenetics shortlist for implementation in clinical practice, Clin. Chem. 63(7) (2017) 1204–1213; https://doi.org/10.1373/clinchem.2016.264986 Search in Google Scholar

11 B. Planelles, C. Margarit, M. D. Inda, P. Ballester, J. Muriel, J. Barrachina, R. Ajo, M. D. Esteban and A. M. Peiró, Gender based differences, pharmacogenetics and adverse events in chronic pain management, Pharmacogen. J. 20(2) (2020) 320–328; https://doi.org/10.1038/s41397-019-0118-9 Search in Google Scholar

12 K. Goodyear, C. L. Haass-Koffler and D. Chavanne, Opioid use and stigma: The role of gender, language and precipitating events, Drug Alc. Depen. 185 (2018) 339–346; https://doi.org/10.1016/j.drugalcdep.2017.12.037 Search in Google Scholar

13 M.-T. Ruiz-Cantero, M. Blasco-Blasco, E. Chilet-Rosell and A. M. Peiró, Gender bias in therapeutic effort: from research to health care, Farm. Hospital 44 (2020) 109–113. Search in Google Scholar

14 S. S. Asl, A. Roointan, H. Bergen, S. Amiri, P. Mardani, N. Ashtari, R. Shabani and M. Mehdizadeh, Opioid receptors gene polymorphism and heroin dependence in Iran, Basic Clin. Neurosci. 9(2) (2018) 101–106; https://doi.org/10.29252/nirp.bcn.9.2.101 Search in Google Scholar

15 P. Bach and D. Hartung, Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders, Addict. Sci. Clin. Pract. 14(1) (2019) Article ID 30 (11 pages); https://doi.org/10.1186/s13722-019-0158-0 Search in Google Scholar

16 S. Sarkar, R. Lal, M. Varshney and Y. P. S. Balhara, Tramadol for maintenance in opioid dependence: A retrospective chart review, J. Opioid Manag. 13(5) (2017) 329–334; https://doi.org/10.5055/jom.2017.0401 Search in Google Scholar

17 R. K. Lanier, A. Umbricht, J. A. Harrison, E. S. Nuwayser and G. E. Bigelow, Evaluation of a transdermal buprenorphine formulation in opioid detoxification, Addiction (Abingdon) 102(10) (2007) 1648–1656; https://doi.org/10.1111/j.1360-0443.2007.01944.x Search in Google Scholar

18 J. Muriel, C. Margarit, B. Planelles, M. J. Serralta, C. Puga, M. D. Inda, E. Cutillas, D. Morales, J. F. Horga and A. M. Peiró, OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients, Ann. N. Y. Acad. Sci. 1425(1) (2018) 82–93; https://doi.org/10.1111/nyas.13735 Search in Google Scholar

19 E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gøtzsche and J. P. Vandenbroucke, The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies, J. Clin. Epidemiol. 61(4) (2008) 344–349; https://doi.org/10.1016/j.jclinepi.2007.11.008 Search in Google Scholar

20 American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5th ed., Washington, D.C. 2013. Search in Google Scholar

21 J. Fernández-Miranda, Guide to the Treatment of Opioid Dependence, Socidrogalcohol, Palma de Mallorca 2007, p. 118. Search in Google Scholar

22 S. Mercadante, A. Casuccio, F. Fulfaro, L. Groff, R. Boffi, P. Villari, V. Gebbia and C. Ripamonti, Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study, J. Clin. Oncol. 19(11) (2001) 2898–2904; https://doi.org/10.1200/jco.2001.19.11.2898 Search in Google Scholar

23 S. H. Jones, G. Thornicroft, M. Coffey and G. Dunn, A brief mental health outcome scale-reliability and validity of the global assessment of functioning (GAF), Br. J. Psych. 166(5) (1995) 654–659; https://doi.org/10.1192/bjp.166.5.654 Search in Google Scholar

24 H. M. McCormack, D. J. Horne and S. Sheather, Clinical applications of visual analogue scales: a critical review, Psychol. Med. 18(4) (1988) 1007–1019. Search in Google Scholar

25 R. A. Moore and H. J. McQuay, Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids, Arthr. Res. Ther. 7(5) (2005) R1046–R1051; https://doi.org/10.1186/ar1782 Search in Google Scholar

26 J. Barrachina, J. Muriel, C. Margarit, B. Planelles, P. Ballester, M. Richart-Martínez, E. Cutillas, T. Zandonai, D. Morales and A. M. Peiró, Global pain state questionnaire: Reliability, validity, and gender gap, Arch. Intern. Med. Res. 4 (2021) 91–113; https://doi.org/10.26502/aimr.0061 Search in Google Scholar

27 P. Mozzicato, MedDRA An overview of the medical dictionary for regulatory activities, Pharm. Med. 23(2) (2009) 65–75; https://doi.org/10.1007/BF03256752 Search in Google Scholar

28 W. Häuser, B. Morlion, K. E. Vowles, K. Bannister, E. Buchser, R. Casale, J.-F. Chenot, G. Chumbley, A. M. Drewes, G. Dom, L. Jutila, T. O’Brien, E. Pogatzki-Zahn, M. Rakusa, C. Suarez-Serrano, T. Tölle and N. Krčevski Škvarč, European clinical practice recommendations on opioids for chronic noncancer pain – Part 1: Role of opioids in the management of chronic noncancer pain, Eur. J. Pain 25(5) (2021) 949–968; https://doi.org/https://doi.org/10.1002/ejp.1736 Search in Google Scholar

29 C. Taylor, I. Crosby, V. Yip, P. Maguire, M. Pirmohamed and R. M. Turner, A review of the important role of CYP2D6 in pharmacogenomics, Genes 11(11) (2020) Article ID 1295 (22 pages); https://doi.org/10.3390/genes11111295 Search in Google Scholar

30 A. Llerena, P. Dorado, R. Ramírez, I. González, M. Alvarez, E. M. Peñas-Lledó, B. Pérez and L. R. Calzadilla, CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans, Pharmacogen. J. 12(2) (2012) 176–183; https://doi.org/10.1038/tpj.2010.85 Search in Google Scholar

31 A. Gaedigk, S. D. Simon, R. E. Pearce, L. D. Bradford, M. J. Kennedy and J. S. Leeder, The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype, Clin. Pharmacol. Ther. 83(2) (2008) 234–242; https://doi.org/10.1038/sj.clpt.6100406 Search in Google Scholar

32 P. Dorado, M. Cáceres, E. Pozo-Guisado, M. L. Wong, J. Licinio and A. Llerena, Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use, BioTechniques 39(Suppl. 10) (2005) S571–S574; https://doi.org/10.2144/000112044 Search in Google Scholar

33 M. E. G. Naranjo, F. de Andrés, A. Delgado, J. Cobaleda, E. M. Peñas-Lledó and A. LLerena, High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies, Pharmacogen. J. 16(5) (2016) 485–490; https://doi.org/10.1038/tpj.2016.47 Search in Google Scholar

34 J. Mennis, G. J. Stahler and M. J. Mason, Risky substance use environments and addiction: A new frontier for environmental justice research, Int. J. Environ. Res. Public Health 13(6) (2016) Article ID 607 (15 pages); https://doi.org/10.3390/ijerph13060607 Search in Google Scholar

35 M. Gosch, B. Böhmdorfer, U. Benvenuti-Falger, P. Dovjak, B. Iglseder, M. Lechleitner, R. Otto, R. E. Roller and U. Sommeregger, [Polypharmacy and pain treatment], Wien. Med. Wochenschr. 160(11–12) (2010) 286–292; https://doi.org/10.1007/s10354-010-0788-z Search in Google Scholar

36 A. I. Henche Ruiz, Problematic use of prescription opioid drugs: Classification and effective treatments, Med. Clin. 152(11) (2019) 458–465; https://doi.org/https://doi.org/10.1016/j.medcli.2018.10.008 Search in Google Scholar

37 M. D. Cheatle, P. A. Compton, L. Dhingra, T. E. Wasser and C. P. O’Brien, Development of the revised opioid risk tool to predict opioid use disorder in patients with chronic nonmalignant pain, J. Pain 20(7) (2019) 842–851; https://doi.org/10.1016/j.jpain.2019.01.011 Search in Google Scholar

38 C. Els, T. D. Jackson, D. Kunyk, V. G. Lappi, B. Sonnenberg, R. Hagtvedt, S. Sharma, F. Kolahdooz and S. Straube, Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane reviews, Cochrane Database Syst. Rev. 10(10) (2017) Cd012509; https://doi.org/10.1002/14651858.CD012509.pub2 Search in Google Scholar

39 L. Hazell and S. A. Shakir, Under-reporting of adverse drug reactions: a systematic review, Drug Safety 29(5) (2006) 385–396; https://doi.org/10.2165/00002018-200629050-00003 Search in Google Scholar

40 M. Gombert, P. Ballester, A. Segura and A. M. Peiró, Introducing sexual dysfunction in mental care, Expert Opin. Drug Safety 20(1) (2021) 69–79; https://doi.org/10.1080/14740338.2020.1849135 Search in Google Scholar

41 L. LeResche, K. Saunders, S. Dublin, S. Thielke, J. O. Merrill, S. M. Shortreed, C. Campbell and M. R. Von Korff, Sex and age differences in global pain status among patients using opioids long term for chronic noncancer pain, J. Women Health 24(8) (2015) 629–635; https://doi.org/10.1089/jwh.2015.5222 Search in Google Scholar

42 M. Noble, J. R. Treadwell, S. J. Tregear, V. H. Coates, P. J. Wiffen, C. Akafomo, K. M. Schoelles and R. Chou, Long-term opioid management for chronic noncancer pain, Cochrane Database Syst. Rev. No. 1 (2010) CD006605; https://doi.org/10.1002/14651858.CD006605.pub2 Search in Google Scholar

43 N. Kozlov and H. T. Benzon, Role of gender and race in patient-reported outcomes and satisfaction, Anesthesiol. Clin. 38(2) (2020) 417–431; https://doi.org/10.1016/j.anclin.2020.01.012 Search in Google Scholar

44 F. K. H. Sørup, R. Eriksson, D. Westergaard, J. Hallas, S. Brunak and S. E. Andersen, Sex differences in text-mined possible adverse drug events associated with drugs for psychosis, J. Psycho-pharmacol. (Oxford) 34(5) (2020) 532–539; https://doi.org/10.1177/0269881120903466 Search in Google Scholar

45 E. Mura, S. Govoni, M. Racchi, V. Carossa, G. N. Ranzani, M. Allegri and R. H. van Schaik, Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?, J. Pain Res. 6 (2013) 331–353; https://doi.org/10.2147/jpr.s42040 Search in Google Scholar

46 K. Blum, M. Oscar-Berman, Z. Demetrovics, D. Barh and M. S. Gold, Genetic addiction risk score (GARS): molecular neurogenetic evidence for predisposition to reward deficiency syndrome (RDS), Mol. Neurobiol. 50(3) (2014) 765–796; https://doi.org/10.1007/s12035-014-8726-5 Search in Google Scholar

47 L. Dean and M. Kane, Codeine Therapy and CYP2D6 Genotype, in Medical Genetics Summaries (Eds. V. M. Pratt, S. A. Scott, M. Pirmohamed, B. Esquivel, M. S. Kane, B. L. Kattman and A. J. Malheiro), National Center for Biotechnology Information, Bethesda (MD) 2012, p. 25. Search in Google Scholar

48 E. B. Ettienne, A. Ofoegbu, M. K. Maneno, J. Briggs, G. Ezeude, S. Williams, C. Walker and E. Chapman, Pharmacogenomics and opioid use disorder: clinical decision support in an African American cohort, J. Nat. Med. Assoc. 111(6) (2019) 674–681; https://doi.org/10.1016/j.jnma.2019.09.006 Search in Google Scholar

49 M. A. Bahar, D. Setiawan, E. Hak and B. Wilffert, Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6, Pharmacogenomics 18(7) (2017) 701–739; https://doi.org/10.2217/pgs-2017-0194 Search in Google Scholar

50 C. R. Fulton, Y. Zang, Z. Desta, M. B. Rosenman, A. M. Holmes, B. S. Decker, Y. Zhang, J. T Callaghan, V. M. Pratt, K. D. Levy, B. T. Gufford, P. R. Dexter, T. C. Skaar and M. T. Eadon, Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial, Pharmacogenomics 20(6) (2019) 397–408; https://doi.org/10.2217/pgs-2018-0205 Search in Google Scholar

51 G. Cochran, J. Bruneau, N. Cox and A. J. Gordon, Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic, Subst. Abuse 41(3) (2020) 269–274; https://doi.org/10.1080/08897077.2020.1787300 Search in Google Scholar

52 National Institute on Drug Abuse (NIDA), Cooperation Between Physicians and Pharmacists May Improve Treatment for Patients with Opioid Use Disorder, 2021; https://nida.nih.gov/news-events/nida-notes/2021/11/cooperation-between-physicians-and-pharmacists-may-improve-treatment-for-patients-with-opioid-use-disorder; last access date September 20, 2022 Search in Google Scholar